Bioenvision reiterated by Stanford at buy

Bioenvision Inc. was reiterated by Stanford Capital Group analyst Aaron Reames at a buy rating with a price target on the stock of $11 per share in anticipation of European approval for its clofarabine in pediatric treatments as early as September or October. Bioenvision shares Wednesday were up $0.07, or 0.79%, at $8.91 on volume of 320,732 shares versus the three-month running average of 327,434 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.